| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T189 |
0-292 |
Sentence |
denotes |
Umifenovir Anti-influenza membrane fusion inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. |
| T190 |
293-449 |
Sentence |
denotes |
The manuscript is publicly available but still to be peer reviewed [30] • Comparison of umifenovir vs. standard of care in patients with COVID-19 pneumonia. |
| T191 |
450-499 |
Sentence |
denotes |
Open-label RCT (NCT04260594, not yet recruiting). |
| T192 |
500-568 |
Sentence |
denotes |
Primary endpoint: virus negative conversion rate (follow-up 7 days). |
